ImpediMed LimitedASX: IPD

Cancer survivorship pioneer appointed to scale SOZO

· Issued by ImpediMed Limited via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

ImpediMed Limited has appointed Dr. Nicole Stout as Chief Clinical Innovation Officer to enhance the SOZO Digital Health Platform's adoption in cancer care settings. Dr. Stout is recognized for her extensive experience in cancer rehabilitation and has a strong background in implementing supportive care models. She aims to drive SOZO as a standard of care for cancer survivorship, leveraging her expertise to improve clinical practices. The announcement highlights ImpediMed's commitment to advancing cancer care through innovative technology and clinical strategies.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/cancer-survivorship-pioneer-appointed-to-scale-sozo

Watch ImpediMed explain itImpediMed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29, 2026 · From 3:43 · Cancer Survivorship and New Clinical Standards

Release

ImpediMed Limited Suite 31C, 12-18 Tryon Rd Lindfield NSW 2070 Australia E: [email protected] W: impedimed.com 27 October 2026 Companies Announcements Office Australian Securities Exchange ImpediMed appoints cancer survivorship pioneer Dr. Nicole Stout to drive SOZO as standard of...

ImpediMed Limited on 6ix

Earlier from ImpediMed

Later from ImpediMed

All ImpediMed news releases